Shiba Inu faces modest price forecasts, but could MAGAX deliver bigger gains for its 4,000+ early investors than SHIB’s breakout in 2020?Shiba Inu faces modest price forecasts, but could MAGAX deliver bigger gains for its 4,000+ early investors than SHIB’s breakout in 2020?

Shiba Inu Price Prediction: Is MAGAX About To Make More Gains For 4,000+ Early Investors Than SHIB Did In 2020?

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Shiba Inu Main2

Shiba Inu Price Outlook in 2025

Shiba Inu’s price predictions for late 2025 are mixed. Currently at $0.000013, SHIB could reach $0.0000139 this year, with some analysts forecasting $0.0001 by 2030.

At the same time, bearish models keep SHIB as low as $0.0000122 in 2025, while optimistic outlooks imagine it spiking to $0.000155–$0.00016 if strong market activity reemerges. In the long term, the idea of SHIB ever hitting $0.01 looks increasingly unrealistic given its vast supply, even with token burns and Shibarium ecosystem upgrades in play.

Lessons From SHIB’s 2020 Breakout

When Shiba Inu first made headlines in 2020, few expected it to become one of the biggest meme coins in history. Back then, early investors who bought fractions of a cent watched their portfolios balloon thousands of percent as speculative demand exploded.

chart4262

SHIB historical chart | CoinMarketCap

That parabolic run was fueled by social media hype, retail FOMO, and a growing sense that SHIB was “the next Dogecoin.” However, after years of volatility, SHIB now faces tougher questions: can it reinvent itself with features like Shibarium, ShibaSwap, and gaming, or will it remain tied to unpredictable hype cycles?

MAGAX Steps Into the Meme Economy

While SHIB grapples with limited growth potential, Moonshot MAGAX (MAGAX) is positioning itself as the next-generation meme-to-earn token. Unlike SHIB, which rose primarily through speculation, MAGAX introduces real utility through its AI-powered Loomint engine, which rewards both meme creators and promoters for creating viral content.

MAGAX 426426

MAGAX’s presale, now in Stage 3 at $0.000318, has drawn over 4,000 early investors, raising more than $119,000 of its $186,034 target. Its rising token price in each stage ensures greater potential for early buyers.

Projections suggest a 141× ROI potential, mirroring the kind of exponential gains SHIB rice once offered in its earliest days.

Why MAGAX Could Outperform SHIB’s Legacy

Unlike SHIB, MAGAX blends meme culture with governance, staking, and deflation. Holders vote on changes and gain from referral/booster programs.

Security is also a cornerstone. MAGAX has been audited by Certik, the world’s leading blockchain and smart contract auditing firm, with zero critical issues, and its internal audits reinforce investor confidence. This transparency stands in sharp contrast to SHIB’s early days, when skepticism was widespread.

With partnerships across Web3, AI-driven fraud protection, and an expanding roadmap that includes staking, meme leaderboards, and DAO governance, MAGAX is pitching itself not just as another meme token — but as the foundation of a meme economy.

A Unique Window for Early Investors

For over 4,000 early backers, the MAGAX presale feels like déjà vu, except this time, the project has a clearer roadmap than SHIB ever did in 2020. Each stage of the presale drives prices higher, shrinking supply and rewarding early movers. At today’s entry price of $0.000318, the cost of entry is still low enough to imagine exponential growth once MAGAX lists publicly.

Can MAGAX achieve SHIB-like viral adoption? If so, its tokenomics, AI utility, and community incentives could lead to returns surpassing SHIB’s historic run for early investors.

Don’t Miss Stage 3: Secure Your MAGAX Tokens Today

Shiba Inu may still command a loyal community, but its price outlook in 2025 suggests limited upside compared to its early years. MAGAX, on the other hand, is positioning itself as the meme economy’s next breakout, with real AI-driven utility, a CertiK audit, and over 4,000 investors already on board.

For those who missed SHIB in 2020, Moonshot MAGAX may represent the closest opportunity to relive that kind of explosive upside; this time with stronger foundations.

Don’t wait for Stage 4. Secure your MAGAX tokens now before the next price hike.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09